Get Sample Report @ https://www.wiseguyreports.com/sample-request/815653-hemochromatosis-pipeline-review-h2-2016
Hemochromatosis – Pipeline Review, H2 2016
Hemochromatosis is an iron disorder in which the body simply loads too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C and history of diabetes, heart disease, or liver disease.
Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Hemochromatosis.
Hemochromatosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hemochromatosis (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Hemochromatosis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hemochromatosis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hemochromatosis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hemochromatosis (Genetic Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hemochromatosis (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hemochromatosis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Hemochromatosis Overview 6
Therapeutics Development 7
Pipeline Products for Hemochromatosis – Overview 7
Pipeline Products for Hemochromatosis – Comparative Analysis 8
Hemochromatosis – Therapeutics under Development by Companies 9
Hemochromatosis – Therapeutics under Investigation by Universities/Institutes 10
Hemochromatosis – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hemochromatosis – Products under Development by Companies 13
Hemochromatosis – Products under Investigation by Universities/Institutes 14
Hemochromatosis – Companies Involved in Therapeutics Development 15
Ionis Pharmaceuticals Inc 15
La Jolla Pharmaceutical Company 16
Protagonist Therapeutics Inc 17
Hemochromatosis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
CN-128 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
IONISTMPRSS-6LRx – Drug Profile 28
Product Description 28
Mechanism Of Action 28
Access Report @ https://www.wiseguyreports.com/reports/815653-hemochromatosis-pipeline-review-h2-2016
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: